News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Verinata Health, Inc. Announces Agreement With Teva Pharmaceutical Industries Limited (TEVA) in Collaboration With MOR Institute for Medical Data to Commercialize the verifi® Prenatal Test in Israel


7/1/2013 8:50:31 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifiĀ® non-invasive prenatal test1 in Israel. The MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifiĀ® prenatal test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality. The MOR Institute, which is a wholly-owned subsidiary of Clalit Health Services, will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Pregnancy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES